尿蛋白标志物在非泌尿系统肿瘤研究中的进展  

Research progress of urinary protein markers in human non-urogenital system tumors

作　　者：蔡梦[1] 赵晓航[1] 孙玉琳[1] 

机构地区：[1]国家癌症中心/中国医学科学院北京协和医学院肿瘤医院,北京100021

出　　处：《生命科学》2016年第11期1337-1346,共10页Chinese Bulletin of Life Sciences

基　　金：国家重点基础研究发展计划(2014CBA-02002);国家自然科学基金项目(81572365;81372591;81572840)

摘　　要：尿液来源于血液,除泌尿系统外,还可以反映身体其他脏器、器官的生理或病理改变。随着蛋白质检测分析技术的进步,健康人尿液中的蛋白质数量被认为有5 000种以上。由于其可以通过非侵入性的方式大量收集,近七八年来,大量的研究开始使用尿液作为非泌尿系统肿瘤标志物研究的重要样本。总结了尿蛋白作为肿瘤标志物来源的优缺点,以及11种常见非泌尿系统肿瘤中发现的尿蛋白标志物,并对尿蛋白标志物的临床应用前景进行了归纳分析与展望,以期促进这些潜在标志物的临床应用以及这一领域的发展。Urine is derived from the blood, therefore, it can reflect the alternation of physiology and pathology in human organs besides urogenital system. Along with the development of protein analysis technology, the amount of urinary proteins in healthy people is believed to be more than 5000. Because urine can be collected non-invasively, over the past eight years, numerous studies have started to use urine as an important sample for tumor biomarker research in the non-urogenital system tumors. In this review, we summarized the advantages and disadvantages of urinary protein markers. And the urinary markers in 11 kinds of common tumors are systematically summarized which may accelerate the clinical application of these potential biomarkers and promote the development and progress of this field in the future.

关 键 词：尿液 蛋白标志物 早期诊断标志物 中枢神经系统肿瘤 呼吸系统肿瘤 消化系统肿瘤 妇科肿瘤 

分 类 号：Q52[生物学—生物化学] R37[医药卫生—病原生物学]